These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23383026)

  • 1. Using central IRBs for multicenter clinical trials in the United States.
    Flynn KE; Hahn CL; Kramer JM; Check DK; Dombeck CB; Bang S; Perlmutter J; Khin-Maung-Gyi FA; Weinfurt KP
    PLoS One; 2013; 8(1):e54999. PubMed ID: 23383026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.
    Check DK; Weinfurt KP; Dombeck CB; Kramer JM; Flynn KE
    Clin Trials; 2013 Aug; 10(4):560-7. PubMed ID: 23666951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.
    Saginur R; Dent SF; Schwartz L; Heslegrave R; Stacey S; Manzo J
    J Clin Oncol; 2008 Mar; 26(9):1479-82. PubMed ID: 18349399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Institutional Review Board dilemma: responsible for safety monitoring but not in control.
    DeMets DL; Fost N; Powers M
    Clin Trials; 2006; 3(2):142-8. PubMed ID: 16773956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application for academic multicenter studies at German ethical review boards].
    Gökbuget N; Naumann R;
    Onkologie; 2013; 36 Suppl 2():29-35. PubMed ID: 23549034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central IRBs: why are some institutions reluctant to sign on?
    McNeil C
    J Natl Cancer Inst; 2005 Jul; 97(13):953-5. PubMed ID: 15998943
    [No Abstract]   [Full Text] [Related]  

  • 8. Reducing the Single IRB Burden: Streamlining Electronic IRB Systems.
    Murray A; Pivovarova E; Klitzman R; Stiles DF; Appelbaum P; Lidz CW
    AJOB Empir Bioeth; 2021; 12(1):33-40. PubMed ID: 32976069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breaking the camel's back: multicenter clinical trials and local institutional review boards.
    Burman WJ; Reves RR; Cohn DL; Schooley RT
    Ann Intern Med; 2001 Jan; 134(2):152-7. PubMed ID: 11177319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of multicenter studies by multiple institutional review boards: characteristics and outcomes for perinatal studies implemented by a multicenter network.
    Abramovici A; Salazar A; Edvalson T; Gallagher N; Dorman K; Tita A;
    Am J Obstet Gynecol; 2015 Jan; 212(1):110.e1-6. PubMed ID: 25088862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problematic variation in local institutional review of a multicenter genetic epidemiology study.
    McWilliams R; Hoover-Fong J; Hamosh A; Beck S; Beaty T; Cutting G
    JAMA; 2003 Jul; 290(3):360-6. PubMed ID: 12865377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time required to review research protocols at 10 Veterans Affairs Institutional Review Boards.
    Varley PR; Feske U; Gao S; Stone RA; Zhang S; Monte R; Arnold RM; Hall DE
    J Surg Res; 2016 Aug; 204(2):481-489. PubMed ID: 27565086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical conduct of palliative care research: enhancing communication between investigators and institutional review boards.
    Abernethy AP; Capell WH; Aziz NM; Ritchie C; Prince-Paul M; Bennett RE; Kutner JS
    J Pain Symptom Manage; 2014 Dec; 48(6):1211-21. PubMed ID: 24879998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional review board barriers and solutions encountered in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now Study: a national multicenter practice-based implementation trial.
    Maclaughlin EJ; Ardery G; Jackson EA; Ives TJ; Young RB; Fike DS; Carter BL
    Pharmacotherapy; 2013 Sep; 33(9):902-11. PubMed ID: 23649880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing a Central IRB Model in a Multicenter Research Network.
    Burr JS; Johnson AR; Vasenina V; Bisping S; Coleman RW; Botkin JR; Dean JM
    Ethics Hum Res; 2019 May; 41(3):23-28. PubMed ID: 31108575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.
    Vardeny O; Hernandez AF; Cohen LW; Franklin A; Baqai M; Palmer S; Bierer BE; Cobb N
    Clin Trials; 2019 Jun; 16(3):290-296. PubMed ID: 30866676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paradoxical problem with multiple-IRB review.
    Menikoff J
    N Engl J Med; 2010 Oct; 363(17):1591-3. PubMed ID: 20942660
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches to facilitate institutional review board approval of multicenter research studies.
    Marsolo K
    Med Care; 2012 Jul; 50 Suppl():S77-81. PubMed ID: 22692264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are central institutional review boards the solution? The National Heart, Lung, and Blood Institute Working Group's report on optimizing the IRB process.
    Mascette AM; Bernard GR; Dimichele D; Goldner JA; Harrington R; Harris PA; Leeds HS; Pearson TA; Ramsey B; Wagner TH
    Acad Med; 2012 Dec; 87(12):1710-4. PubMed ID: 23095928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consent form heterogeneity in cancer trials: the cooperative group and institutional review board gap.
    Koyfman SA; Agre P; Carlisle R; Classen L; Cheatham C; Finley JP; Kuhrik N; Kuhrik M; Mangskau TK; O'Neill J; Reddy CP; Kodish E; McCabe MS
    J Natl Cancer Inst; 2013 Jul; 105(13):947-53. PubMed ID: 23821757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.